Rhythm Pharma's Imcivree Wins UK Approval For Obesity, Hunger Control

Britain's Medicines & Healthcare Products Regulatory Agency (MHRA) has approved Rhythm Pharmaceuticals Inc RYTM Imcivree (setmelanotide) for obesity and the control of hunger.
Related: Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations.
The approval covers adults and children six years of age & above, with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or biallelic leptin receptor (LEPR) deficiency.
Imcivree was selected for evaluation as a "Highly Specialized Technology" by the National Institute for Health and Care Excellence (NICE).
NICE is scheduled to review the dossier for Imcivree in December 2021.
Guidance for coverage of Imcivree under the U.K.'s National Health Service (NHS) is anticipated in Q2 of 2022.
Related content: Benzinga's Full FDA Calendar.
Price Action: RYTM stock is down 1.19% at $12.42 during the market session on the last check Wednesday.

Momentum86.98

GrowthNot Available

QualityNot Available

Value2.50

Short

Medium

Long